JJC8-091

Chemical compound

JJC8-091
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

JJC8-091 is a chemical compound that acts as a potent and selective dopamine receptor modulator. It has been primarily studied for its potential therapeutic effects in neurological disorders such as Parkinson's disease and schizophrenia.

Chemical Structure

Chemical structure of JJC8-091

JJC8-091 is characterized by its unique chemical structure, which includes a piperazine ring attached to a dihydroindenyl group. This configuration is crucial for its activity at dopamine receptors, particularly the D2 and D3 subtypes.

Pharmacology

JJC8-091 functions as a partial agonist at dopamine D2 and D3 receptors. This means it can activate these receptors but to a lesser extent than the endogenous ligand, dopamine. This property allows it to modulate dopaminergic activity in the brain, which is beneficial in conditions where dopamine levels are dysregulated.

Mechanism of Action

The compound's partial agonist activity at D2 and D3 receptors helps to stabilize dopamine signaling. In conditions like Parkinson's disease, where dopamine is deficient, JJC8-091 can enhance dopaminergic activity. Conversely, in conditions like schizophrenia, where there may be excessive dopaminergic activity, it can act to dampen this overactivity.

Therapeutic Potential

JJC8-091 has been investigated for its potential use in treating Parkinson's disease, where it may help alleviate motor symptoms by enhancing dopaminergic transmission. Additionally, its role in modulating dopamine receptors makes it a candidate for treating schizophrenia, particularly in managing symptoms related to dopamine dysregulation.

Research and Development

Research on JJC8-091 is ongoing, with studies focusing on its efficacy, safety, and pharmacokinetic properties. Animal models have shown promising results, but further clinical trials are necessary to establish its therapeutic potential in humans.

Related Compounds

JJC8-091 is part of a broader class of compounds known as dopamine receptor modulators. Other compounds in this class include aripiprazole and brexpiprazole, which are used clinically for similar indications.

Related Pages

• Dopamine receptor
• Parkinson's disease
• Schizophrenia
• Partial agonist